Savoie, Mary Lynn
Mayo Clinic
University of Calgary, Calgary, AB, Canada.
Citations 2
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
Jain, Tania , Estrada‐Merly, Noel, Salas, María Queralt , Kim, Soyoung , DeVos, Jakob D. , Chen, Min , Fang, Xi , Kumar, Rajat , Elmariah, Hany , Aljurf, Mahmoud , Badar, Talha , Ballen, Karen K. , Bredeson, Christopher , DeFilipp, Zachariah , Farhadfar, Nosha , Farhan, Shatha , Gandhi, Arpita , Ganguly, Siddhartha , Hamilton, Betty K. , Inamoto, Yoshihiro , Jamy, Omer , Kharfan‐Dabaja, Mohamed A. , Krem, Maxwell M. , Lad, Deepesh , Malone, Adriana K. , Pawarode, Attaphol , Poel, Marjolein van der , Rizzieri, David A. , Savoie, Mary Lynn , Seo, Sachiko , Solh, Melhem , Üstün, Celalettin , Verdonck, Leo F. , Wirk, Baldeep , Bejanyan, Nelli , Jones, Richard J., Nakamura, Ryotaro , Scott, Bart L. , Saber, Wael , Gupta, Vikas , Salas, M Queralt , Elmariah, Hany , Bacher, Ulrike , Badar, Talha , Bhatt, Vijaya Raj , DeFilipp, Zachariah , Dholaria, Bhagirathbhai R , Farhan, Shatha , Hamad, Nada , Hamilton, Betty K , Inamoto, Yoshihiro , Jamy, Omer , Juckett, Mark , Kharfan-Dabaja, Mohamed A , Krem, Maxwell M , Al Malki, Monzr M , Malone, Adriana K , Murthy, Hemant S , Patel, Sagar , Perales, Miguel-Angel , Ringden, Olov , Rovó, Alicia , Savani, Bipin N , Savoie, Mary Lynn , Seo, Sachiko , Ustun, Celalettin , Verdonck, Leo F , Bejanyan, Nelli , Nishihori, Taiga , Nakamura, Ryotaro , Scott, Bart , Gupta, Vikas , Jain, Tania , Kim, Soyoung , Andrade‐Campos, Marcio , Agrawal, Vaibhav , Badawy, Sherif M. , Beitinjaneh, Amer , Bhatt, Vijaya Raj , Dholaria, Bhagirathbhai , Gergis, Usama , Grunwald, Michael R. , Hamad, Nada , Iqbal, Madiha , Liesveld, Jane L. , Malki, Monzr M. Al , Murthy, Hemant S. , Ortí, Guillermo, Patel, Sagar S. , Perales, Miguel‐Angel , Ringdén, Olle , Savani, Bipin N. , Wingard, John R. , Nishihori, Taiga , Oran, Betül
Blood Advances | June 25, 2024 | Volume: 8 | Issue: 16 | Pages: 4281-4293
10.1182/bloodadvances.2024013451
Abstract We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant Research registry data for HCTs done between 2013 and 2019. In all 1597 patients, the use of haploidentical donors increased from 3% in 2013 to 19% in 2019. In study-eligible 1032 patients who received peripheral blood grafts for chronic-phase myelofibrosis, 38% of recipients of haploidentical HCT were non-White/Caucasian. Matched sibling donor (MSD)–HCTs were associated with superior overall survival (OS) in the first 3 months (haploidentical hazard ratio [HR], 5.80 [95% confidence interval (CI), 2.52-13.35]; matched unrelated (MUD) HR, 4.50 [95% CI, 2.24-9.03]; mismatched unrelated HR, 5.13 [95% CI, 1.44-18.31]; P < .001). This difference in OS aligns with lower graft failure with MSD (haploidentical HR, 6.11 [95% CI, 2.98-12.54]; matched unrelated HR, 2.33 [95% CI, 1.20-4.51]; mismatched unrelated HR, 1.82 [95% CI, 0.58-5.72]). There was no significant difference in OS among haploidentical, MUD, and mismatched unrelated donor HCTs in the first 3 months. Donor type was not associated with differences in OS beyond 3 months after HCT, relapse, disease-free survival, or OS among patients who underwent HCT within 24 months of diagnosis. Patients who experienced graft failure had more advanced disease and commonly used nonmyeloablative conditioning. Although MSD-HCTs were superior, there is no significant difference in HCT outcomes from haploidentical and MUDs. These results establish haploidentical HCT with posttransplantation cyclophosphamide as a viable option in myelofibrosis, especially for ethnic minorities underrepresented in the donor registries.
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission
Rashidi, Armin , Hamadani, Mehdi , Zhang, Mei-Jie , Wang, Hai-Lin, Abdel‐Azim, Hisham , Aljurf, Mahmoud , Assal, Amer , Bashey, Asad, Beitinjaneh, Amer , Bejanyan, Nelli , Bolaños‐Meade, Javier , Byrne, Michael , Cahn, Jean‐Yves, Cairo, Mitchell S. , Ciurea, Stefan O. , Copelan, Edward A. , Daly, Andrew , Diaz, Miguel-Angel, Farhadfar, Nosha , Ganguly, Siddhartha , Hahn, Theresa , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Holland, H. Kent, Hossain, Nasheed , Kanakry, Christopher G. , Kharfan‐Dabaja, Mohamed A. , Khera, Nandita , Martino, Rodrigo , Munker, Reinhold , Murthy, Hemant S. , Nakamura, Ryotaro , Nathan, Sunita , Palmisiano, Neil , Patel, Sagar S. , Pidala, Joseph, Olin, Rebecca L. , Olsson, Richard F. , Ringdén, Olle , Rizzieri, David A. , Rowe, Jacob M. , Savoie, Mary Lynn , Seo, Sachiko , Shaffer, Brian C. , Singh, Anurag K. , Solh, Melhem , Stockerl‐Goldstein, Keith , Verdonck, Leo F. , Wagner, John L. , Waller, Edmund K. , Litzow, Mark R. , Weisdorf, Dan, Saber, Wael , Weisdorf, Daniel J. , Wagner, John E. , Gale, Robert P , Hashmi, Shahrukh K , Hildebrandt, Gerhard C , Kharfan-Dabaja, Mohamed A., McGuirk, Joseph , Murthy, Hemant S , Nishihori, Taiga , Patel, Sagar , Olsson, Richard F , Ringden, Olov , Savoie, Mary Lynn , Wagner, John , Waller, Edmund K , Sandmaier, Brenda M , Litzow, Mark R. , Weisdorf, Dan , Hamadani, Mehdi , Assal, Amer , Martino, Rodrigo , Zhang, Mei‐Jie , Bajel, Ashish R. , Battiwalla, Minoo , Bhatt, Vijaya Raj , Cahn, Jean‐Yves , Cutler, Corey S. , Gale, Robert Peter , Grunwald, Michael R. , Koç, Yener , Lazarus, Hillard M. , Lee, Jong Wook , Maertens, Johan A. , McGuirk, Joseph P. , Nishihori, Taiga , Oran, Betül , Schultz, Kirk R. , Lima, Marcos de , Romee, Rizwan , Rashidi, Armin , Stockerl-Goldstein, Keith
Blood Advances | June 14, 2019 | Volume: 3 | Issue: 12 | Pages: 1826-1836
10.1182/bloodadvances.2019000050
Abstract HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy–based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor–based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease–donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy–based Haplo-HCT vs MSD using calcineurin inhibitor–based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.